What is the dosage of Egrifta?

Egrifta is available in 1 dosages, including 2 mg Injection

What does Egrifta treat?

Egrifta treats HIV-Associated Lipodystrophy Syndrome

What is Egrifta made of?

Egrifta contains tesamorelin which is a Growth Hormone Releasing Factor Analog

How is Egrifta administered?

Egrifta is administered as a Injectable

Dosage & Administration Drug label Prior authorization Financial assistance

Patient education

Egrifta

(tesamorelin)

tesamorelin 2 MG Injection [Egrifta]

NO BLACK BOX WARNING

Dosage & administration

* The recommendations in this prescribing information only apply to EGRIFTA SV (tesamorelin for injection) 2 mg per vial formulation. For recommendations for tesamorelin for injection 1 mg per vial formulation, see the EGRIFTA prescribing information. These two formulations and strengths have differences in the dosage, the number of vials required to prepare a dose, reconstitution instructions, and storage requirements. .
* The dose of EGRIFTA SV is 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously once daily.
* Inject EGRIFTA SV into the abdomen, rotating injection sites.
* Use only the diluent provided, Sterile Water for Injection, USP, to reconstitute EGRIFTA SV.
* Reconstitute one vial of lyophilized powder with 0.5 mL of diluent. Mix by rolling the vial gently in your hands for 30 seconds. Do not shake.
* Inspect the reconstituted vial visually for particulate matter and discoloration. Use only if the solution is clear, colorless and without particulate matter.
* Administer 0.35 mL of EGRIFTA SV immediately following reconstitution and throw away any unused solution and diluent.

drug label

Egrifta prescribing information

Have more Egrifta questions?

Submit MSL Request

Learn More

Need to report an Egrifta issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Egrifta Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

NOT PROVIDED BY BRANDCoverage Authorization Appeals

Learn More

Benefits investigation

Egrifta Support Enrollment Form

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Egrifta Financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Egrifta Patient education

Getting started on Egrifta

Instructions For Use: Reduction of Excess Belly Fat In HIV+ With Lipodystrophy

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient toolkit

About Egrifta SV

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Stories

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Doctor Discussion Guide

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Learn More

Can't find what you're looking for?

Our trained staff can help you:

Please note:

Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.